SCHEDULE 13G/A: Acorn Bioventures Reports 5.3% Stake in Jasper Therapeutics
Amendment to Beneficial Ownership Report
Acorn Bioventures and related entities, managed by Anders Hove, have reported a combined beneficial ownership of 5.3% in Jasper Therapeutics, Inc. common stock.
Summary
- Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove collectively reported beneficial ownership of Jasper Therapeutics, Inc. common stock.
- Anders Hove, as the manager of the general partners for both Acorn Bioventures funds, is deemed to beneficially own an aggregate of 1,486,492 shares.
- This aggregate ownership represents 5.3% of Jasper Therapeutics, Inc.'s common stock outstanding.
- The percentage is calculated based on 27,984,039 shares of Common Stock outstanding as of November 6, 2025, as reported in the Issuer's Form 10-Q.
- The shares are held for investment purposes and not with the intent to change or influence control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a factual report of beneficial ownership. The continued significant stake by an institutional investor like Acorn Bioventures can be viewed as a moderately positive signal of confidence in the company, though it does not provide operational or financial performance details.
Positives
- A significant institutional investor, Acorn Bioventures, maintains a substantial stake, indicating continued investment interest in Jasper Therapeutics.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Jasper Therapeutics, Inc.'s future performance or operations.
Industry Context
This filing reflects an institutional investor's position in a biotechnology company. Such filings are common and provide transparency into significant ownership stakes, which can sometimes signal investor confidence or strategic positioning within the sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant beneficial ownership stake by an institutional investor may provide a level of confidence or stability, indicating continued interest from a professional investment group.
Key Dates
| Date | Description |
|---|---|
| 2025-11-06 | Date as of which 27,984,039 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-11-10 | Date Jasper Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025. |
| 2026-01-23 | Date of event which required the filing of this Schedule 13G Amendment No. 1. |
| 2026-01-26 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Jasper Therapeutics, Acorn Bioventures, Anders Hove, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.